Apr 9 |
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
|
Mar 28 |
Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
|
Mar 13 |
11 Oversold NASDAQ Stocks To Buy Right Now
|
Mar 13 |
11 Oversold Healthcare Stocks To Buy Right Now
|
Mar 7 |
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript
|
Mar 6 |
Q4 2023 Seres Therapeutics Inc Earnings Call
|
Mar 5 |
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
|
Mar 5 |
Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023
|
Mar 5 |
Seres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23M
|
Mar 5 |
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
|